Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IN8bio, Inc. (INAB : NSDQ)

• Company Description    IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $2.18 Daily Weekly Monthly 20 Day Moving Average: 239,555 shares Shares Outstanding: 3.03 (millions) Market Capitalization: $6.60 (millions) Beta: 0.00 52 Week High: $27.30 52 Week Low: $2.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -47.72% -50.04% 12 Week -52.27% -59.23% Year To Date -71.78% -73.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 350 5th Avenue Suite 5330 - New York,NY 10118 USA ph: 646-600-6438 fax: - gdschulman@in8bio.com http://www.in8bio.com

• General Corporate Information    Officers William Ho - Chief Executive Officer Alan S. Roemer - Chairman Patrick McCall - Chief Financial Officer and Secretary Peter Brandt - Director Corinne Epperly - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45674E208 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 3.03 Most Recent Split Date: 6.00 (0.03:1) Beta: 0.00 Market Capitalization: $6.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.43 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 65.00% vs. Previous Quarter: -75.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -218.85 12/31/24 - -226.34 ROA 06/30/25 - - 03/31/25 - -139.59 12/31/24 - -144.44 Current Ratio 06/30/25 - - 03/31/25 - 4.30 12/31/24 - 4.08 Quick Ratio 06/30/25 - - 03/31/25 - 4.30 12/31/24 - 4.08 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.13 12/31/24 - 6.00 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.02 Debt-to-Capital 06/30/25 - - 03/31/25 - 1.34 12/31/24 - 2.00

Powered by Zacks Investment Research ©